Urinary neopterine excretion in patients with genital cancer

Bichler, A; Fuchs, Dietmar; Hausen, Arno; Hetzel, H; König, Klaus; Wächter, Helmut

doi:10.1016/s0009-9120(82)90421-0

Cited by 25 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the findings of Sichler et al (17), who reported a good correlation between radiotherapy and chemotherapy and urinary neopterin excretion in cancer patients, we found no correlation between the^ success of chemotherapy and serum or urinary neopterin levels. When testicular tumour patients, known to be tumour free, received adjuvant chemotherapy, a significant increase in serum and urinary neopterin values after chemotherapy was found.…”

Section: Discussioncontrasting

confidence: 99%

Neopterin as Tumour Marker Serum and Urinary Neopterin Concentrations in Malignant Diseases

Kuzmits¹,

Ludwig²,

Legenstein³

et al. 1986

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Summary: Serum and urinary neopterin concentrations were measured in 142 patients suffering from various inalignant diseases. Increased serum and urinary neopterin levels were found in 48% and 55% of patients respectively. Neopterin showed sufficient sensitivity in the detection of haematological disorders and hypernephroma, whereas the sensitivity of neopterin was rather poor in patients with other solid tumours.Comparison of serum -fetoprotein (AFP) and human chorionic gonadotropin (HCG) concentrations and serum or urinary neopterin levels in testicular cancer patients showed that determination of neopterin provides no further Information in the managemerit of these patients.In testicular cancer patients receiving adjuvant chemotherapy, a significant increase in serum (p < 0.005) and urinary (p < 0.0005) neopterin concentrations was measured after chemotherapy, reflecting the release of neopterin from macrpphages during the damage by cytotoxic drugs. In the adjuvant testicular tumour patients, known to be tumour free, l out of 16 patients showed elevated serum and 3 out of 15 patients showed false positive urinary neopterin levels.False positive serum (24%) and urinary (37%) neopterin values were also obtained in 28 patients with various nonmalignant diseases, but no evidence for an inflammatory process. In 23 patients with inflammatory diseases pathological serum and urinary neopterin levels were measured in 55% and 59% respectively.When a RIA was compared with a HPLC method, higher urinary neopterin values were obtained with the RIA, indieating that non-oxidized pterines are also determined by the RIA method.In conclusion, neopterin might be a helpful biological marker in monitoring patients with malignant haematological disorders and renäl cell carcinoma, but provides no additional Information in other solid tumours studied.

show abstract

Section: Discussioncontrasting

confidence: 99%

Neopterin as Tumour Marker Serum and Urinary Neopterin Concentrations in Malignant Diseases

Kuzmits¹,

Ludwig²,

Legenstein³

et al. 1986

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, recent in vitro studies (Huber et al 1983(Huber et al , 1984 have shown that neopterin is especially secreted by macrophages and may be a useful marker in assessing the activation of the T cell-macrophage axis. Increased urinary neopterin levels have been observed in patients with malignant tumors and viral diseases (Wachter et al 1979b;Rokos et al 1980;Hausen et al 1981;Bichler et al 1982), but urinary neopterin levels in liver diseases in Japan where hepatocellular carcinoma (HCC) is not infrequent have not yet been extensively studied. …”

mentioning

confidence: 99%

Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma.

Kawasaki

Watanabe

Yamada

et al. 1988

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Urinary neopterin levels were measured by high-performance liquid chromatography in 15 patients with liver cirrhosis, 18 patients with hepatocellular carcinoma and 20 normal subjects. The mean levels of urinary neopterin in patients with hepatocellular carcinoma were significantly elevated (p <0.01) compared to those in cirrhotics and normal subjects, but did not significantly differ between cirrhotics and normal subjects. Urinary neopterin levels correlated significantly with tumor size in patients with hepatocellular carcinoma but not with serum a-fetoprotein. Hepatocellular carcinoma patients with high urinary neopterin levels appeared to have more serious hepatic dysfunction than those with normal urinary neopterin levels, and moreover, there was a significant difference (p <0.05) in survival between the two groups. These findings suggest that urinary neopterin excretion may be a good biochemical marker to assess the progression of tumor and a useful prognostic indicator in patients with hepatocellular carcinoma, urinary neopterin ; a-fetoprotein ; hepatocellular carcinoma Neopterin is an intermediate in the biosynthesis of tetrahydrobiopterin which plays an important role in the synthesis of neurotransmitters such as catecholamines and serotonin. The urinary excretion of pteridines including neopterin is considered to be an indicator of cell proliferation (Wachter et al. 1980) and to be associated with the presence of malignant growth (Wachter et al. 1979a). Moreover, recent in vitro studies (Huber et al. 1983(Huber et al. , 1984 have shown that neopterin is especially secreted by macrophages and may be a useful marker in assessing the activation of the T cell-macrophage axis. Increased urinary neopterin levels have been observed in patients with malignant tumors and viral diseases (Wachter et al. 1979b;Rokos et al. 1980;Hausen et al. 1981;Bichler et al. 1982), but urinary neopterin levels in liver diseases in Japan where hepatocellular carcinoma (HCC) is not infrequent have not yet been extensively studied.

show abstract

“…The clinical Utility of the urinary neopterin measurement was improved in patients with gynaecological tumours (69). There was a significant difference (p < 0.01) between the mean values of 63 untreated tumour patients and 96 healthy women compared in each case to the age-paired group.…”

Section: Excretion Of Pteridines In Patients With Malignant Diseasesmentioning

confidence: 90%

“…In order to assess neoplasias the upper normal limits of urinary pteridines must be statedL Rokos and coworkers (45) considered values of neopterin ab ve 447 μπιοΐ/τηοΐ creatinine ΐο be abnormal. H wever, this limit which was based on the estimation of neopterin and biopterin following an oxidation Step prior to analysis by HPLC, did not take into account the sex-and age-dependent variations of urinary neopterin levels (49,67,69). Recommended upper levels of normal excretion, which do take into account the sex-and age-dependence of urinary neopterm have recently been stated (49,69), Table 3 shows the mean and median values and the upper confidence limits for eaeh sex and age group.…”

Section: Excretion Of Pteridines From Cells Plants and Animalsmentioning

confidence: 99%

“…H wever, this limit which was based on the estimation of neopterin and biopterin following an oxidation Step prior to analysis by HPLC, did not take into account the sex-and age-dependent variations of urinary neopterin levels (49,67,69). Recommended upper levels of normal excretion, which do take into account the sex-and age-dependence of urinary neopterm have recently been stated (49,69), Table 3 shows the mean and median values and the upper confidence limits for eaeh sex and age group. These limits, calculated according toLieberni nn (70), include with 95% probability 97.5% of healthy subjects, thus enabling the accurate Interpretation of results.…”

Section: Excretion Of Pteridines From Cells Plants and Animalsmentioning

confidence: 99%

See 1 more Smart Citation

Pteridines in the Assessment of Neoplasia

Hausen¹,

Wachter²

1982

CCLM

Self Cite

View full text Add to dashboard Cite

Summary: Biological processes which inight explain the association of pteridine excretion with proliferation are still unknown. Difficulties in the analysis and the determination of naturally occurring pteridines are described. The best quantitative estimations were achieved when measurement of non-reduced forms was attempted. The performance characteristics of such a method for neppterin by high performance liquid chromatography on reversed phase are given. Enhanced proliferation and dedifferentiation in cell cultures and organisms is paralleled by excretion of unconjugated pteridines into the medium or urine. Urinary neopterin in healthy subjects and in patients with benign diseases was only significantly raised in patients with viral diseases. Howevei, an elevation of urmary neopterin occurred in a wide variety of malignant diseases. In haematologic neoplasias correlatipns of neopterin values to clinicäl features, to tumour staging, and to laboratory data were apparent. The clinicäl Utility of neopterin measurement was also demonstrated in patients with gynaecologic tumours, particularly in patients with ovarian carcinoma. In both homogenepus patient groups the neopterin assay may provide an additional aid for prognosis and for monitoring therapy. Comparison of the neopterin assay with already established tumour marker substances at least revealed no inferiority in sensitivity. The present results justify extensive investigations in prder to eväluate further the clinicäl applicäbility of the neopterin assay. Pteridine in der Diagnostik von Neoplasien

show abstract

Urinary neopterine excretion in patients with genital cancer

Cited by 25 publications

References 13 publications

Neopterin as Tumour Marker Serum and Urinary Neopterin Concentrations in Malignant Diseases

Neopterin as Tumour Marker Serum and Urinary Neopterin Concentrations in Malignant Diseases

Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma.

Pteridines in the Assessment of Neoplasia

Contact Info

Product

Resources

About